PPARD and polyp: Gupta et al. showed thatexposure of Apcmin mice to10 mg/kg of GW501516, a high-affinity PPARδ-selective agonist, led to a two-foldincrease in polyp number in the small intestine [101].The most prominent effect was on polyp size, mice treated with the PPARδ activator had a five-fold increase inthe number of polyps larger than 2 mm, suggesting that PPARδ activation primarily affected the rateof polyp growth rather than initiating polyp formation.